総説・解説等 - 籠谷　勇紀

血液がんを標的としたCAR-T細胞療法の現状と課題

籠谷 勇紀

炎症と免疫（先端医学社） 31 （ 4 ） 283 - 288 2023年07月

多発性骨髄腫に対するCAR-T細胞療法の研究開発動向

籠谷 勇紀

血液内科（科学評論社） 86 （ 5 ） 676 - 681 2023年05月

キメラ抗原受容体遺伝子改変T細胞療法の改良

籠谷 勇紀

腫瘍内科（科学評論社） 31 （ 4 ） 462 - 467 2023年04月

Introduction: Redefining T-cell Exhaustion Special Issue

Kagoya Y., Togashi Y.

International Immunology （International Immunology）  34 （ 11 ） 545 - 546 2022年11月

ISSN  09538178

• Access to Document (DOI)

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

Yusuke Ito, Yuki Kagoya

Cancer Science 113 （ 11 ） 3664 - 3671 2022年11月

責任著者

　概要を見る

Recent advancements in cancer immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cell therapy and immune checkpoint therapy, have significantly improved the clinical outcomes of patients with several types of cancer. To broaden its applicability further and induce durable therapeutic efficacy, it is imperative to understand how antitumor T cells elicit cytotoxic functions, survive as memory T cells, or are impaired in their effector functions (exhausted) at the molecular level. T cell properties are regulated by their gene expression profiles, which are further controlled by epigenetic architectures, such as DNA methylation and histone modifications. Multiple studies have elucidated specific epigenetic genes associated with T-cell phenotypic changes. Conversely, exogenous modification of these key epigenetic factors can significantly alter T cell functions by extensively altering the transcription network, which can be applied in cancer immunotherapy by improving T cell persistence or augmenting effector functions. As CAR-T cell therapy involves a genetic engineering step during the preparation of the infusion products, it would be a feasible strategy to additionally modulate specific epigenetic genes in CAR-T cells to improve their quality. Here, we review recent studies investigating how individual epigenetic factors play a crucial role in T-cell biology. We further discuss future directions to integrate these findings for optimal cancer immunotherapy.

PRDM1遺伝子ノックアウトによる長期生存型抗腫瘍T細胞の作製

籠谷 勇紀

血液内科（科学評論社） 85 （ 5 ） 753 - 758 2022年11月

Dissecting the heterogeneity of exhausted T cells at the molecular level.

Yuki Kagoya

International Immunolology 34 （ 11 ） 547 - 553 2022年10月

筆頭著者, 最終著者, 責任著者

　概要を見る

Our understanding of mechanisms underlying T-cell exhaustion has been refined by analysis of exhausted T cells at the molecular level. The development and functions of exhausted T cells are regulated by a number of transcription factors, epigenetic factors and metabolic enzymes. In addition, recent work to dissect exhausted T cells at the single-cell level has enabled us to discover a precursor exhausted T-cell subset equipped with long-term survival capacity. Starting from the analysis of mouse models, the existence of precursor exhausted T cells has also been documented in human T cells in the context of chronic virus infections or tumors. Clinical data suggest that evaluating the quality of exhausted T cells on the basis of their differentiation status may be helpful to predict the therapeutic response to inhibition of programmed death 1 (PD1). Moreover, beyond immune-checkpoint blockade, novel therapeutic approaches to re-invigorate exhausted T cells have been explored based on molecular insights into T-cell exhaustion. Here I will discuss key molecular profiles associated with the development, maintenance and differentiation of exhausted T cells and how these findings can be applicable in the field of cancer immunotherapy.

ユニバーサルCAR-T細胞の開発

籠谷 勇紀

Precision medicine 5 （ 10 ） 913 - 916 2022年09月

T細胞疲弊の分子機構

吉川 聡明, 籠谷 勇紀

臨床免疫・アレルギー科 78 （ 2 ） 187 - 193 2022年08月

NF-κBシグナルによる白血病幹細胞制御

籠谷 勇紀

血液内科 （科学評論社）  70 （ 3 ） 373 - 378 2015年03月

ISSN  2185-582X